Next Investors logo grey

MMJ appoints pharmaceutical experts to drive expansion

Published 16-JUN-2016 11:58 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Medical Cannabis company MMJ PhytoTech (ASX:MMJ) has added to its senior management and advisory personnel Stanislav Sologubov as Chief Executive Officer of Satipharm Switzerland and John Hollister as a strategic pharmaceutical consultant.

The key appointments are in line with MMJ’s intended evolution towards a pharmaceutical business model in which the company plans to commercialise Medical Grade Cannabis and high potential cannabis based therapeutics products to the international market and in line with medical cannabis laws.

Managing Director of MMJ, Andreas Gedeon had the following to say in the announcement to the market:

“We are very pleased to be appointing two highly regarded healthcare industry professionals to assist with our transition into a leading pharmaceutical company.

“We view our expansion into key European markets as a significant near-term value driver for the business, and the appointments of Stanislav and John respectively, are a core component of this strategy.

“The Board is also very encouraged by the continued progress being made in respect to our MMPR licensing applications in Canada, and we expect to be in a position to provide further updates on these approvals shortly..

“Also noteworthy, is that the granting of Marijuana for Medical Purposes Regulations licenses has served as a significant value driver for a number of listed companies operating in the sector, and we expect the approval of our applications to be a key catalyst for MMJ in the near-term.”

Stanislav Sologubov

As CEO of Satipharm Switzerland, Sologubov will be focused on driving European sales growth of Satipharm’s medical cannabis consumer health products.

With a proven track record of delivering sales growth and extensive industry knowledge and contacts developed from over 15 years’ experience working with global healthcare companies including the likes of Johnson & Johnson and Bausch + Lomb, Sologubov has been brought on board to boost MMJ’s market presence in Europe.

The essential aim for MMJ is to establish a cash flow stream from its Swiss based subsidiary (Satipharm) to fund MMJ’s clinical development and pharmaceutical processing initiatives.

Initially Sologubov’s primary focus will be on growing Satipharm’s Gelpell® Gastro-Resistant Microgel CBD Oral capsule sales in Europe.

Next Investors Image

John Hollister

Hollister brings a wide array of skills to the MMJ team with more than 25 years’ experience as a healthcare industry executive working for large pharmaceutical, biotechnology and medical device companies.

Highly prized is Hollister’s extensive experience in various stages of the commercialisation process with products related to the healthcare industry and hence has been appointed as a consultant to provide framework on pharmaceutical manufacturing across key business divisions in Canada, Israel and Switzerland.

Hollister’s most recent position held was CEO of US-based biopharmaceutical company Nemus Bioscience Inc.

With licensing applications progressing for the Marijuana for Medical Purposes Regulations at MMJ’s Lucky Lake facility, production at both Duncan and Lucky Lake facilities is set to up scaled upon receiving license approval.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.